KHÓ TIÊU CHỨC NĂNG CÓ DÙNG ITOPRIDE HYDROCHLORIDE

Abstract

Objectives: This study aimed to assess the QoL of FD patients before and after 4 weeks of treatment with itopride hydrochloride and to explore related factors influencing QoL in this patient group. Methods: A prospective, longitudinal study was conducted on 74 FD patients diagnosed according to the ROME IV criteria. Patients were treated with itopride hydrochloride at a dose of 150 mg/day for 4 weeks. QoL was measured using the Short-Form Nepean Dyspepsia Index (SF-NDI) at two time points: before and after treatment. Data were analyzed using SPSS 26.0 software. Results: The mean baseline SF-NDI score was 52.57 ± 18.47, which decreased to 25.68 ± 6.71 after 4 weeks of treatment. The mean improvement in the total SF-NDI score was 26.89 points, which was statistically significant (p < 0.001). Improvement was observed across all SF-NDI domains, with the highest improvement in the "work/study" domain. No significant association was found between the degree of SF-NDI improvement and factors such as gender, BMI, smoking habits, alcohol consumption, coffee use, physical activity, or NSAID use (p > 0.05). Patients with the overlap subtype had the highest baseline SF-NDI score (61.77 ± 16,86) and the greatest improvement after treatment. Conclusion: Four weeks of treatment with itopride hydrochloride significantly and comprehensively improved the QoL of FD patients, particularly in the overlap subtype, which has the highest symptom burden.